Introduction
Increased awareness about prostate cancer and the symptoms of prostatic diseases will have contributed in part to the rise in prostate-specific antigen (PSA) testing 1 in the UK during the past decade. However, there has been no uniform health education message, and levels of awareness and willingness to seek medical advice will vary across the population. Studies have shown that a proportion of urinary symptoms, some severe, are not reported to GPs, [2] [3] [4] and there is variation in the level of awareness. 5 The Cancer Reform Strategy 6 has endorsed the National Awareness and Early Diagnosis Initiative that will co-ordinate a programme of activity to support local interventions to raise public awareness of the signs and symptoms of early cancer and encourage people to seek help sooner. Evaluation is essential to ensure effective strategies. 7 The Department of Health (DH) Prostate Cancer Advisory Group approved a prostate awareness pilot initiative, which aimed to increase knowledge and awareness of problems with the prostate, including prostate cancer, in men aged >50 years, and to encourage reporting of symptoms to GPs without causing a sudden rise in GP workload. ContinYou, a charity with expertize in organizing educational programmes, was funded by DH to organize the pilot intervention, launched on 2 October 2006. Two independent evaluations were funded separately from the initiative. The qualitative study reported on the design and methods of promoting the initiative and assessed the achievements and limitations with its delivery in reaching men across socio-economic groups and those at increased risk of prostate cancer. 8 It was found that nearly all intervention materials had been taken in community venues but not in all pharmacies and surgeries. Some interviewees showed attitudinal change.
This paper reports the findings of an epidemiological evaluation, which investigated changes in consultation rates for urological symptoms, rates of prescriptions issued for urological conditions and PSA requests in primary care over time in Coventry. A randomized controlled trial could not be conducted because the intervention used local media to target the whole population of Coventry. However, the results in Coventry were compared with those in three control areas.
Methods
The intervention messages and programme The messages of the intervention were drawn up by the Prostate Cancer Advisory Group ( Table 1 ). The pilot intervention lasted for a 4-week period from 2 October 2006 and aimed to provide sustained health messages among men aged >50 without causing high levels of anxiety or a sudden rise in use of GP services. Within the target group, attention was paid to those considered at high risk of prostate cancer: men with a family history of the disease and those from African and African Caribbean populations. The intervention aimed to address inequalities in health by using community development approaches to reach men in deprived wards who, while having lower incidence rates than in affluent areas, have poorer survival. 9 The target area of Coventry Teaching Primary Care Trust (PCT) was chosen because it is a Spearhead PCT, ranking in the highest quartile of areas for deprivation. 10 Data sources and choice of study areas Data on consultations and prescribing were collected from the General Practice Research Database (GPRD) 11 and data on PSA tests from the pathology laboratory at the main hospital serving each study area. In addition to Coventry, the PCTs of Croydon, Ealing and Harrow were selected from PCTs covered by the GPRD 12 because of similar distributions of age, sex and some measures of social deprivation with those in Coventry. Rates of PSA testing were studied in the same PCTs.
Selection of GP practices and time periods
The number of practices per PCT in the GPRD was limited to 4/63 in the Coventry Teaching PCT, 3 
Data collection
The GPRD collated data by month, PCT, age group and type of consultation. GP consultations for urological symptoms likely to be associated with increased awareness arising from the intervention messages were identified using standardized codes (Appendix). Prescriptions issued for urological conditions were identified using standard product and generic names (Appendix). Men were excluded if registered at the study practices for <6 months prior to the month of consultation or recorded with prostate disease prior to each month under analysis. The GPRD limited the data to men with an acceptable quality of data following the practice up-to-standard date. For each practice, this is the date when it meets a defined minimum number of criteria for data quality covering completeness, continuity and plausibility of recorded data. The PSA data consisted of individual records with specimen number, date of birth, test details and general practice postcode. The postcodes were linked to values of the Index of Multiple Deprivation 13 and to ward level data on the proportion of men in each of the ethnic groups white, African or African Caribbean and Asian (comprising Indian, Pakistani, Bangladeshi and other Asian populations) calculated from the 2001 Census. Data on Quality and Outcomes Framework (QOF) points per practice were obtained for total achievement results, a points score of a total of 1050, which includes points for clinical care, good organization, positive patient experience and extra services. 14 
Outcome measures and analysis
Monthly and 6 months rates were analysed for the following:
1. GP consultations and prescriptions issued for urological symptoms or conditions per 100 personyears. Person-years at risk was calculated by the GPRD summing each patient's contribution (in days) for that particular month. The sum of all patient contributions (stratified by age, time period and study area) was then divided by 365.25 to give the total person time in person-years. 2. GP PSA testing per 100 men registered. The number of PSA requests for a given age group and practice was divided by the number of registered men in 2005 in each practice. The latter were provided by age (45-64, 65-74 and 75-84 years) and practice.
In simple tabulations, results for three 6-month periods were analysed according to availability of data: . Monthly data were studied in graphs and Poisson regression analyses. For the PSA data, a Poisson regression model was designed with three segments of time, each of 6 months (a piecewise function was used: mkspline, STATA, release 7). Rates of PSA testing were studied by PSA level (<2 ng/ml, 2-3.9 ng/ml and >4 ng/ml) and by characteristics of the general practices. The square root of the percentages of African and African Caribbean and Asian associated with each practice provided an approximate normal distribution for the Poisson regression analyses.
Sample size estimates
In a population of 75 000 men in the target and each control area, there would have been 90% power to detect a difference in the rate of PSA testing of 3.0 versus 3.3 per 100 men at the 5% level of significance either between areas or between time periods within areas. The available population for studying consultation rates was smaller, and it was not possible to predict statistical power in advance since the rate of GP consultations for urological conditions was not known. Following observation of the trends in rates of PSA testing and consultations over time, the main analyses were Poisson regression of time trends.
Results

Rates of GP consultations and prescribing
There was no significant difference in the six monthly rate of consultations for urological symptoms in Coventry between the first pre-pilot and pilot periods ( Table 2) . Similar results were found in the control areas. Time trends for monthly rates of consultations within age groups did not change after the launch of the pilot in Coventry (Fig. 1a) . There was a significant higher six monthly rate of prescriptions issued for urological conditions in Coventry in the pilot period (22 per 100 person-years) compared with the first non-pilot period (19 per 100 person-years) after adjusting for age (P = 0.03, Table 2 ). However, plots of the monthly rate of prescriptions issued for urological conditions showed that the rate increased over time during the non-pilot period and then reached a plateau during the pilot period (Fig. 1b) .
In Poisson regression analyses, consultation rates for urological symptoms and the rate of prescriptions issued for urological conditions increased significantly with age (P < 0.001, Table 3 ) but the trend in the rates with time did not differ between Coventry and the control areas. Similar results were found when 'first ever' consultation rates for urological symptoms and rates of prescriptions were studied. First ever was defined for each man as having had no previous consultations for specific urological symptoms or diseases in the period for which they had been registered at the study practice prior to the month being analysed.
The rates of prescriptions issued for urological conditions were higher than the consultation rates for urological symptoms because prescribing is routinely recorded and includes issue of repeat prescriptions, whereas a continuation of symptoms will not necessarily be recorded at each follow-up consultation for an episode of illness.
PSA testing
Overall, 69% (146/213) of practices agreed for their PSA data to be analysed: 80, 74, 56 and 64% in Coventry, Croydon, Ealing and Harrow, respectively. Of the 146 practices, 44 were in Coventry. The age distribution of the registered male populations was very similar in each area with >69% being aged 45-64 years. There were a total of 20 528 PSA records received from the laboratories in the 18 months from 1 December 2005. There were 78 duplicates, 130 recorded as female or gender not known and 6 with missing date of birth excluded from the analyses.
The effect of the pilot on rates of PSA testing was studied in Table 4 and Figure 2 . The six monthly rates of PSA testing in Coventry increased significantly from 3.3 per 100 men in the first non-pilot period to 4.1 per 100 men in the pilot period (P < 0.001) after adjusting for age (Table 4) . Similar increases were seen in Croydon (P = 0.006) and Harrow (P = 0.012), and there was no change in Ealing. In Coventry, the relation of the monthly rate of testing to time did not change after the launch of the pilot and did not differ between age groups (Fig. 2) .
In Poisson regression analyses in Coventry, there was no significant change in the slope of rate of testing by month in the pilot period compared with the first non-pilot period. In the control areas, there was a significant increase in the slope in the pilot period compared with the first non-pilot period (P = 0.01).
In Coventry and two control areas (Croydon and Harrow), there was a significant increase in the rate of testing for each group of PSA levels (P < 0.001, P < 0.001 and P = 0.052 for rates for PSA levels <2, 2-3.9 and > 4 ng/ml, respectively). In cross-sectional analyses of data from the pilot period, the rate of PSA testing increased significantly with age (P < 0.001) and Family Practice-an international journal was significantly different between areas after allowing for practice characteristics. Rates of testing were raised in practices associated with more affluent areas (P = 0.003) and slightly lower QOF points (P < 0.001), with a high percentage of Asian population (P = 0.02) and with a low percentage of Africans and African Caribbeans (P = 0.003).
Discussion
Summary of main findings
In Coventry during the pilot period, there was no significant increase in the monthly rates of GP consultations for urological symptoms or of prescriptions issued for urological conditions or the rate of GP PSA requests. The rate of PSA testing was rising before the pilot was launched both in the Coventry and in the control areas. This was probably part of the national trend. 1 An increase in the consultation rate for urological symptoms in the pilot period might have been associated with increase in the rate of raised levels of PSA but increases were found for all levels of PSA.
Strengths and limitations of the study
Interpretation of these results depends in part on evidence of the effectiveness of the pilot to deliver materials, raise awareness and change behaviour. As discussed by Nutbeam, 7 it is not possible to conduct a randomized trial in a community-based programme, which uses multifacet methods including publicity. Indepth individual-based survey methods can be used to study directly whether initiatives increase awareness and knowledge, leading men to seek medical attention. However, such methods are costly and have their own limitations: potential bias arising from variation in response rates by social deprivation, errors in recall of consultations and bias in answers to questions about health-seeking behaviour.
As there were delays in the commissioning of the qualitative evaluation, information on the distribution and delivery of the intervention strategies in this pilot could not be fed into the development of the campaign strategy and ensure delivery targets were met. One target group, men with a family history of prostate problems, was not reached directly although some would have been exposed to the messages channelled through community approaches.
The GPRD and pathology laboratories are known to provide good quality data 1, 12 and the GPRD has been used to study disease presentation and cancer care. 15 The use of routinely available data allowed a timely preliminary assessment of the impact of the pilot, and the results provide guidance for future research. The inclusion of control areas allowed us to take into account trends in GP consultations occurring elsewhere during the study period. Although local or national initiatives might have affected awareness of prostate symptoms and GP consultations during the pilot period, we are unaware of any taking place in either the pilot or the control areas. In future evaluation studies, methods for collating information on such initiatives need further investigation to establish a network of sources and routine recording of local activities.
Given the observed rate of consultations for urological symptoms, the available sample sizes would only have had 80% power to detect an increase of a third or more in the rate in the study area. The small numbers of GPRD practices are unlikely to be representative of their PCTs. The mean socio-economic status scores for the practices within each area were slightly high relative to the whole PCTs of Coventry, Ealing and Harrow and slightly low for Croydon. The practices providing PSA data in Coventry had a similar proportion of practices with one partner to that found nationally (30% in the present study and 27% 16 ), but this was not so in Harrow (14%) and Ealing (47%). The QOF points were generally high in all areas. Health initiatives such as screening 17 are more readily taken up by less deprived populations, so despite the bias in the sample of practices, it is more likely that an effect of the pilot would have been in our study populations.
The age range for men with PSA data (45-84 years, restricted by the collated numbers of men registered per practice provided by the PCT database) had a slightly lower limit than that for men included in the GPRD data (50-84 years). Given that the pilot was aimed at men aged >50and assuming that there was no effect in men below this age, it is possible that studying the wider age range could have diluted any effect from the pilot. However, the PSA data were analysed within age bands, and no effect from the pilot could be detected by age. Moreover, it is very likely that the pilot messages would have been seen by younger men, so it cannot be assumed that any effects could only be detected in men aged >50.
In a future evaluation, it would be helpful to link consultation data directly to requests for diagnostic tests including PSA. It was not feasible to perform such analyses in the present study because the numbers of GPRD practices within each area were too small for the number of consultations to provide adequate numbers of PSA tests for analysis.
As the pilot aimed to ensure that its health messages were sustainable, it is possible that effects of the health education messages may have become evident after the 6-month period studied here, particularly for prescribing. However, longer follow-up will increase the possibility of other factors, particularly new initiatives and news in the media, affecting GP consultations.
Comparison with existing literature
Few studies have evaluated prostate health education initiatives. In England and Wales, a study that investigated the impact of a brief patient decision aid on men's knowledge, attitudes and intention to have a PSA test showed that knowledge increased but men did not alter their behaviour. 18 In the USA, evaluation studies found that initiatives have not always managed to increase awareness and knowledge of prostate symptoms in men. 19, 20 Some success in awareness initiatives has been achieved in skin cancer programmes, particularly Australia. 21 In Queensland, Australia, 22 the SkinWatch programme aimed to raise public awareness about skin cancer and encourage attendance at open screening clinics. There was extensive evaluation of all aspects of the programme to study satisfaction and acceptability among community leaders, medical staff and attenders to the clinics and community awareness that increased by 30%. In England and Scotland in the 1990s, the Mole Watcher campaign aimed to promote early detection of melanoma by informing the public about the early signs of the disease. There was a sharp rise in use of GP 23 and hospital services 24 in the first few weeks after the launch but these effects gradually decreased. In a European study 25 in 21 countries, screening for colorectal cancer was less likely to be taken up by people who had a low awareness of risk and younger age groups. Willingness to discussing bowel symptoms varied between countries.
National initiatives to increase cancer awareness are underway in several countries. In the UK, several initiatives are outlined in the first annual report of the Cancer Reform Strategy, 6 including national surveys of awareness of cancer symptoms, and the launch of the National Awareness and Early Detection Initiative, which is co-ordinating a programme of support for local interventions to raise awareness and improve methods to measure and evaluate interventions.
Conclusions
The fact that there was no sudden increase in GP consultation rates during the pilot should be somewhat reassuring but there remain questions about the effectiveness of the pilot to reach all target groups and to effectively change health-seeking behaviour. The qualitative study demonstrated the importance of early planning of evaluation and more accountability of effectiveness of delivery of the initiative. The epidemiological study demonstrated effective use of routinely collected data to study medical outcome measures in general practice relevant to the aims of the pilot initiative.
